HemaSphere
(Jun 2022)
P1134: OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA POST-CBTK INHIBITOR THERAPY IN THE UNITED STATES AND JAPAN: A STUDY OF TWO REAL-WORLD DATABASES
- S. Rai,
- L. Hess,
- Y. Chen,
- P. Abada,
- H. Konig,
- R. Walgren,
- Y. Tanizawa,
- Z. Cai,
- M. Tajimi
Affiliations
- S. Rai
- 1 Kindai University Faculty of Medicine, Osakasayama, Japan
- L. Hess
- 2 Eli Lilly and Company, Indianapolis, United States of America
- Y. Chen
- 2 Eli Lilly and Company, Indianapolis, United States of America
- P. Abada
- 2 Eli Lilly and Company, Indianapolis, United States of America
- H. Konig
- 2 Eli Lilly and Company, Indianapolis, United States of America
- R. Walgren
- 2 Eli Lilly and Company, Indianapolis, United States of America
- Y. Tanizawa
- 3 Eli Lilly Japan K.K, Kobe, Japan
- Z. Cai
- 3 Eli Lilly Japan K.K, Kobe, Japan
- M. Tajimi
- 3 Eli Lilly Japan K.K, Kobe, Japan
- DOI
-
https://doi.org/10.1097/01.HS9.0000847404.28922.1a
- Journal volume & issue
-
Vol. 6
pp.
1024
– 1025
WeChat QR code